KCNH2 and torsades de pointes: Ivabradine inhibits the human ether-a-go-go-related gene (hERG) that encodes the pore-forming subunit of the rapid component of the delayed rectifier K+ channel and torsades de pointes in patients [33], although other studies failed to observe increasing QT when heart rate correction was performed [34].